800-TEMPLE-MED Schedule Appointment
SEARCH TEMPLE HEALTH

A Study to Evaluate the Efficacy and Safety of GSK3915393 in Participants With Idiopathic Pulmonary Fibrosis (IPF)

view all Clinical Trials

Overview

Idiopathic Pulmonary Fibrosis is a chronic lung disease which causes scarring of the lungs and difficulty in breathing. GSK3915393 is a new medicine, which is being tested in participants with IPF for the first time. The study will assess the safety and effectiveness of GSK3915393 in IPF participants.

Clinical Trial Information

Protocol

TIRB#: 31703

Phase

2

Condition(s)

Interstitial Lung Disease (ILD), Idiopathic Pulmonary Fibrosis (IPF)

Investigator

Gerard Criner, MD

Coordinator

Debasree Sana Boral

Visit clinicaltrials.gov for full description.

Contact

For more information about this trial or to inquire about eligibility, email [email protected] or call 215-707-1359.

Full Title

A Phase 2, Randomized, Double-Blind, Placebo Controlled, Parallel Group Study (TRANSFORM) to Evaluate the Efficacy and Safety of GSK3915393 in Participants With Idiopathic Pulmonary Fibrosis (IPF)